Atrial Fibrillation
Read Time: 2 mins

78/The ganglionated plexuses and their electrophysiological phenomena – Evidence for their role in pathogenesis of atrial fibrillation

Copy Link
Published Online: Oct 3rd 2008 European Journal of Arrhythmia & Electrophysiology. 2019;5(Suppl. 1):abstr78
Authors: MY Kim (Presenting Author) - Myocardial Function, Imperial College London, London, UK; B Sandler - Myocardial Function, Imperial College London, London, UK; KM Leong - Imperial College NHS Trust, London, UK; V Luther - Imperial College NHS Trust, London, UK; L Malcolme-Lawes - Imperial College NHS Trust, London, UK; MB Sikkel - Imperial College NHS Trust, London, UK; A Sohaib - Imperial College NHS Trust, London, UK; M Koa-Wing - Imperial College NHS Trust, London, UK; FS Ng - Myocardial Function, Imperial College London, London, UK; NA Qureshi - Imperial College NHS Trust, London, UK; ZI Whinnett - Imperial College NHS Trust, London, UK; DR Tomlinson - Derriford Hospital, University Hospitals Plymouth NHS Trust, Plymouth, UK; RJ Hunter - St Bartholomew’s Hospital, Barts Health NHS Trust, London, UK; NS Peters - Myocardial Function, Imperial College London, London, UK; PB Lim - Imperial College NHS Trust, London, UK; NWF Linton - Imperial College NHS Trust, London, UK; P Kanagaratnam - Imperial College NHS Trust, London, UK
Quick Links:
Article Information

Introduction: The left atrial ganglionated plexus (GP) are implicated in atrial fibrillation (AF) and can be located by high frequency endocardial stimulation (HFS). In order to understand the role of GP in AF pathogenesis, we report reproducible electrophysiological phenomena seen during GP stimulation and ablation.

Methods: Ninety-five patients with paroxysmal AF with or without previous pulmonary vein isolation were studied. All had detailed global left atrial high frequency stimulation (HFS) mapping around the left atrium with a 3.5 mm tip ablation catheter to identify GPs. 20-pole PV catheter was inserted into the nearest pulmonary vein (PV) to where HFS was being tested. CARTOTM was used to create 3D electroanatomic map of the left atrium and HFS tested sites were tagged according to their response. HFS causing ectopy/atrial tachycardia/AF were tagged ’ectopy-triggering GP’ (ET-GP). Patients in sinus rhythm were paced at a fixed rate and HFS delivered within the local atrial refractory period (10 V, 40 Hz, 80 ms, 20 ms delay from pacing stimulus) to identify ET-GP. If in AF, continuous HFS was performed (10 V, 20 Hz continuously for up to 10 s) to identify atrioventricular-dissociating GP (AVD-GP) which was defined as average RR prolongation of >50% during HFS from the baseline RR interval. GPs were ablated and re-tested with HFS to confirm loss of effect.

Results: We observed interesting electrophysiological phenomena during mapping and ablation of GPs:


1. Triggering PV tachycardia in isolated veins; 4/41 patients (10%) with previous PV isolation (PVI) had GPs identified in the atria that triggered rapid PV tachycardia with exit block with HFS. One patient had PV tachycardia for >20 mins, whilst the remaining atrium continued in slow SR (Figure 1A).

2. Triggering AF with radiofrequency (RF) energy; 76 patients had RF application at GPs in sinus rhythm. Ten patients (13%) triggered AF with RF application at GPs, which terminated to SR during or immediately after stopping RF (Figure 1B).

3. Terminating induced AF with GP ablation; 36 patients had sustained AF induced by HFS. Nineteen (53%) patients had AF termination during ablation of GP site (Figure 1C).

4. Modification of AF substrate; After GP ablation, 6 patients had continuous HFS tested over ablated GP sites during sinus rhythm. All 6 (100%) could not induce AF with high rate atrial capture from continuous HFS (Figure 1D).

5. Preventing AF recurrence with GP ablation; in one remarkable case, a single GP site was ablated for only 197 secs at the left inferior pulmonary vein ostium in the posterior wall. RF application immediately caused AF. PVs were left electrically connected. The patient has been symptom free and not required repeat ablation for over 4 years.

6. GP activity can recur after ablation; 9 patients with previous GP ablations returned for repeat ablations with symptomatic AF recurrence. At previously ablated GP sites, we re-mapped with HFS to see if any GP recovery. One patient had no recovery of GPs and 8 remaining patients had on average 67% ± 58 of GPs recovered at re-test.

Conclusion: These observations resulting from stimulation and ablation of GP sites identified by HFS, provide further evidence of the importance of the intrinsic cardiac autonomic nervous system in AF pathogenesis.

Further Resources

Share this Article
Related Content In Atrial Fibrillation
  • Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72